1219741-41-9

Upstream product

• 1219741-39-5 methyl 5-[(6-chloro-5-iodo-1-{[2-(trimethylsilyl)ethoxy]-methyl}-1H-benzimidazol-2-yl)oxy]-2-methylbenzoate 

Downstream Products

• 1219741-64-6 methyl 5-{[5-(4-bromophenyl)-6-chloro-1H-benzimidazol-2-yl]oxy}-2-methylbenzoate 
• 1219738-29-0 Methyl 5-({6-chloro-5-[(2-fluorophenyl)ethynyl]-1H-benzimidazol-2-yl}oxy)-2-methylbenzoate 
• 1219741-59-9 methyl 5-{[5-(4-acetylphenyl)-6-chloro-1H-benzimidazol-2-yl]oxy}-2-methylbenzoate 
• 1219741-58-8 methyl 5-{[6-chloro-5-(2-naphthyl)-1H-benzimidazol-2-yl]oxy}-2-methylbenzoate 
• 1219738-82-5 Methyl 5-({6-chloro-5-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1H-benzimidazol-2-yl}oxy)-2-methylbenzoate 

Relevant academic research and scientific papers

NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, Metabolic Syndrome, obesity, hypercholesterolemia, and hypertension